
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is expected to see a temporary delay in their share buybacks but has shown strong performance in win rates and bookings. Meanwhile, their competitor ICLR is facing margin declines but has implemented steps to address the issue and invest in growth opportunities, including a technology partnership and divestment. Both companies are confident in their future success, although risks from emerging technologies remain a potential concern.
Bears say
Icon is facing potential risks, including the possibility of further accounting reviews or restatements which could impact investor confidence and future revenue. Additionally, the company's success may be impacted if it is unable to deliver clinical trials on time or secure sensitive clinical trial data. However, there is potential for upside in the stock due to Icon's strong partnerships with large pharmaceutical companies, stabilizing biopharma funding, and favorable clinical trial trends pointing to increased demand for CRO services. While management has indicated positive net bookings trends, there may still be some concerns about the potential impact of AI on the industry. Overall, the stock is currently trading at a fair value, and we rate it as Hold.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares